Skip to main content
Clinical Trials/NCT01981876
NCT01981876
Completed
Not Applicable

Study of Esophageal Squamous Dysplasia Prevalence at Tenwek Hospital

Tenwek Hospital1 site in 1 country305 target enrollmentOctober 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Esophageal Dysplasia
Sponsor
Tenwek Hospital
Enrollment
305
Locations
1
Primary Endpoint
Percentage rate of subjects with Esophageal Squamous dysplasia calculated as Prevalence
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

Esophageal squamous cell cancer (ESCC) is common in the developing world, and is the leading cancer diagnosis at Tenwek Hospital in southwestern Kenya. The investigators long-term goal is to understand the pathogenesis and risk factors for ESCC in Kenya, and to establish effective screening and prevention programs. The investigators hypothesize that asymptomatic esophageal squamous dysplasia (ESD) is common in their region, and the current protocol is designed to determine the prevalence of ESD in residents of southwestern Kenya.

Detailed Description

The prevalence of esophageal squamous dysplasia will be determined after evaluating pathology reports from unstained lesions and normal biopsies after staining with Lugol's iodine.

Registry
clinicaltrials.gov
Start Date
October 2010
End Date
December 2014
Last Updated
11 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 20 years
  • No dysphagia (subjects will be asked "do you have trouble swallowing food or water? Do they get stuck inside after you swallow?" in their primary language

Exclusion Criteria

  • Cardiac, respiratory, or metabolic disease that would increase the risk of endoscopy: history of myocardial infarction, arrhythmias, chronic obstructive pulmonary disease, diabetes, allergy to lidocaine.
  • Unable or unwilling to provide informed consent.

Outcomes

Primary Outcomes

Percentage rate of subjects with Esophageal Squamous dysplasia calculated as Prevalence

Time Frame: 2 years

Secondary Outcomes

  • percentage of subjects with mild esophageal squamous dysplasia calculated as a prevalence(2 years)
  • percentage of subjects with severe esophageal squamous dysplasia calculated as a prevalence(2 years)
  • percentage of subjects with moderate esophageal squamous dysplasia calculated as a prevalence(2 years)

Study Sites (1)

Loading locations...

Similar Trials